Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with radioligand intensification despite early on-treatment score fluctuations. FACT-P ...

*Likely reflects later-line therapy and selection for biomarker-positive advanced disease. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...

Pooled trials show Pluvicto improves progression-free survival in advanced prostate cancer, without increasing serious adverse events. An examination of data from more than 2500 patients with advanced ...

ProTACT: A first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC.

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...

(UroToday.com) The 2026 European Association of Urology (EAU) Annual Meeting held in London, U.K., was host to the Hormone sensitive metastatic prostate cancer: Thematic Session. Dr. Declan Murphy ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...

Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...